Nascent Biotech, Inc.

Equities

NBIO

US63108Q1013

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 15:14:22 06/06/2024 BST			5-day change	1st Jan Change
0.0969 ^USD	+7.67%		-1.62%	-43.96%

04-16	Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	CI
03-19	Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	CI

Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022

November 10, 2022 at 10:09 pm

Nascent Biotech, Inc. reported earnings results for the second quarter and six months ended September 30, 2022. For the second quarter, the company reported net loss was USD 0.145714 million compared to USD 0.21103 million a year ago.
For the six months, net loss was USD 1.45 million compared to USD 0.661106 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.

Latest news about Nascent Biotech, Inc.

Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	04-16	CI
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	03-19	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	02-06	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	22/08/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	18/08/23	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	02/07/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29/06/23	CI
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	30/05/23	CI
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	28/02/23	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	25/01/23	CI
Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer Trial	10/01/23	CI
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board	20/12/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research	04/10/22	CI
Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer	13/09/22	CI
Nascent Biotech, Inc. announced that it has received $0.2425 million in funding from Platinum Point Capital LLC	07/09/22	CI
Nascent Biotech, Inc. announced that it expects to receive $1.5 million in funding from Yorkville Advisors Global LP	29/08/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	15/06/22	CI
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	14/06/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	04/11/21	CI

Chart Nascent Biotech, Inc.

Duration

Period

More charts

Company Profile

Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. Its initial focus is on patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NASCENT BIOTECH, INC.	-43.96%	16.53M
VERTEX PHARMACEUTICALS INCORPORATED	+18.98%	125B
REGENERON PHARMACEUTICALS, INC.	+14.16%	108B
BIONTECH SE	-3.60%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-11.98%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.99%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.69%	11.1B

Bio Therapeutic Drugs